Related Experiment Video

Updated: Aug 13, 2026

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

The TRPV1 receptor: target of toxicants and therapeutics

Bellina Veronesi1, Marga Oortgiesen

  • 1National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Neurotoxicology Division--Cellular and Molecular Branch, Research Triangle Park, North Carolina 27711, USA. veronesi.bellina@epa.gov

Toxicological Sciences : an Official Journal of the Society of Toxicology
|January 13, 2006
PubMed

Insights

TRPV1 antagonists can unexpectedly increase TRPV1 receptor levels on lung cells, worsening TRPV1-related toxic effects. This study explores the mechanism behind this TRPV1 sensitization, offering insights into pain and inflammation drug development.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Molecular Biology

Background:

  • The Transient Receptor Potential Vanilloid Receptor (TRPV1) is crucial for pain and inflammation signaling.
  • TRPV1's role in these processes makes it a key target for therapeutic intervention.
  • Understanding TRPV1 sensitization and desensitization is vital for drug development.

Purpose of the Study:

  • To investigate how TRPV1 antagonists affect cell surface receptor populations.
  • To elucidate the mechanism behind TRPV1 sensitization induced by antagonists.
  • To examine the consequences of TRPV1 sensitization on toxicity in human lung epithelial cells.

Main Methods:

  • Exposure of human lung epithelial cells to various TRPV1 antagonists.
  • Quantification of cell surface TRPV1 receptor protein levels.
  • Assessment of TRPV1-mediated toxicities.
  • Mechanistic studies to explain observed sensitization.

Main Results:

  • TRPV1 antagonists led to an increase in cell surface TRPV1 receptor protein.
  • This elevation in receptor levels was associated with exacerbated TRPV1-mediated toxicities.
  • A potential mechanistic explanation for TRPV1 sensitization was proposed.

Conclusions:

  • TRPV1 antagonists can induce sensitization, counteracting therapeutic goals.
  • Increased cell surface TRPV1 may enhance cellular responses and toxicity.
  • Further research into TRPV1 antagonist mechanisms is needed for safe and effective pain and inflammation therapies.

More Related Videos

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV412:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

Related Concept Videos

Thermosensation01:43

Thermosensation

Peripheral thermosensation is the perception of external temperature. A change in temperature (on the surface of the skin and other tissues) is detected by a family of temperature-sensitive ion channels called Transient Receptor Potential, or TRP, receptors. These receptors are located on free nerve endings. Those detecting cold temperatures are closer to the surface of the skin than the nerve endings detecting warmth. These thermoTRP channels, while temperature selective, have relatively...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...